Open-label, Single-arm, Phase 2 Study of Initial Treatment With Daratumumab (Darzalex), Carfilzomib (Kyprolis), Lenalidomide (Revlimid) and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2019
Price : $35 *
At a glance
- Drugs Carfilzomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 07 Oct 2019 Status changed from not yet recruiting to recruiting.
- 07 Dec 2018 Planned initiation date changed from 1 Oct 2018 to 1 Jan 2019.
- 13 Aug 2018 Planned initiation date changed from 1 Jun 2018 to 1 Oct 2018.